Hepatitis B Precore Protein: Pathogenic Potential and Therapeutic Promise

키워드

참고문헌 (73)

1. Kane MA, "Global status of hepatitis B immunisation", Lancet, 348, pp.696~ (1996)
2. Lavanchy D., "Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures", J Viral Hepat, 11, pp.97~107 (2004)
3. Kim BK, "HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B", Antivir Ther, 16, pp.1169~1186 (2011)
4. Lai CL, "The natural history of chronic hepatitis B", J Viral Hepat, 14(Suppl 1), pp.6~10 (2007)
5. McMahon BJ, "The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B", Hepatol Int, 3, pp.334~342 (2009)
6. Milich D, "Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection", Hepatology, 38, pp.1075~1086 (2002)
7. Chang C, "Expression of the precore region of an avian hepatitis B virus is not required for viral replication", J Virol, 61, pp.3322~3325 (1987)
8. Chen MT, "A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen", Proc Natl Acad Sci U S A, 101, pp.14913~14918 (2004)
9. Milich DR, "Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?", Proc Natl Acad Sci U S A, 87, pp.6599~6603 (1990)
10. Lok AS, "Chronic hepatitis B", Hepatology, 45, pp.507~539 (2007)
11. Ou JH, "Molecular biology of hepatitis B virus e antigen", J Gastroenterol Hepatol, 12, pp.178~187 (1997)
12. Lin CL, "The clinical implications of hepatitis B virus genotype: recent advances", J Gastroenterol Hepatol, 26(Suppl 1), pp.123~130 (2011)
13. Jia-Horng Kao, "Molecular Epidemiology of Hepatitis B Virus", The Korean Journal of Internal Medicine, 26(3), pp.255~261 (2011), 대한내과학회
14. Yang HI, "Hepatitis B e antigen and the risk of hepatocellular carcinoma", N Engl J Med, 347, pp.168~174 (2002)
15. Visvanathan K, "Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein", Hepatology, 45, pp.102~110 (2007)
16. Dandri M, "New insight in the pathobiology of hepatitis B virus infection", Gut, 61(Suppl 1), pp.6~17 (2012)
17. McMahon BJ, "The natural history of chronic hepatitis B virus infection", Hepatology, 49(5 Suppl), pp.45~55 (2009)
18. Herkel J, "Let it B in viral hepatitis?", J Hepatol, 55, pp.5~7 (2011)
19. Creagh EM, "TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity", Trends Immunol, 27, pp.352~357 (2006)
20. Pahl HL, "Activators and target genes of Rel", NF-kappaB transcription factors, 1999, pp.18, 6853~6866
21. Thompson AJ, "Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response", Immunol Cell Biol, 85, pp.435~445 (2007)
22. Roy CR, "Pathogen subversion of cell-intrinsic innate immunity", Nat Immunol, 8, pp.1179~1187 (2007)
23. Chen Z, "Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients", Clin Immunol, 128, pp.400~408 (2008)
24. Lang T, "The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway", J Hepatol, 55, pp.762~769 (2011)
25. Riordan SM, "Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B", Clin Vaccine Immunol, 13, pp.972~974 (2006)
26. Wu J, "Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells", Hepatology, 49, pp.1132~1140 (2009)
27. Revill P, "Bioinformatic analysis of the hepadnavirus e-antigen and its precursor identifies remarkable sequence conservation in all orthohepadnaviruses", J Med Virol, 82, pp.104~115 (2010)
28. Wrammert J, "Rapid cloning of high-affinity human monoclonal antibodies against influenza virus", Nature, 453, pp.667~671 (2008)
29. Han SH, "Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation", Liver Transpl, 9, pp.182~187 (2003)
30. Neumann AU, "Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells", Hepatology, 52, pp.875~885 (2010)
31. Schilling R, "Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions", J Virol, 77, pp.8882~8892 (2003)
32. Maruyama T, "The serology of chronic hepatitis B infection revisited", J Clin Invest, 91, pp.2586~2595 (1993)
33. Chen M, "Immune tolerance split between hepatitis B virus precore and core proteins", J Virol, 79, pp.3016~3027 (2005)
34. Milich DR, "The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence", J Immunol, 160, pp.2013~2021 (1998)
35. Walsh R, "Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody", Virology, 411, pp.132~141 (2011)
36. Dienes HP, "Analysis of the precore DNA sequence and detection of precore antigen in liver specimens from patients with anti-hepatitis B e-positive chronic hepatitis", Hepatology, 21, pp.1~7 (1995)
37. Kimura T, "Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain", J Biol Chem, 280, pp.21713~21719 (2005)
38. Messageot F, "Proteolytic processing of the hepatitis B virus e antigen precursor. Cleavage at two furin consensus sequences", J Biol Chem, 278, pp.891~895 (2003)
39. Takahashi K, "Immunochemical structure of hepatitis B e antigen in the serum", J Immunol, 130, pp.2903~2907 (1983)
40. Takahashi K, "Full-genome sequence analyses of hepatitis B virus (HBV) strains recovered from chimpanzees infected in the wild: implications for an origin of HBV", Virology, 267, pp.58~64 (2000)
41. Watts NR, "Role of the propeptide in controlling conformation and assembly state of hepatitis B virus e-antigen", J Mol Biol, 409, pp.202~213 (2011)
42. Steven AC, "Structure, assembly, and antigenicity of hepatitis B virus capsid proteins", Adv Virus Res, 64, pp.125~164 (2005)
43. Chen RY, "Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro", Hepatology, 37, pp.27~35 (2003)
44. Lamberts C, "Precore-mediated inhibition of hepatitis B virus progeny DNA synthesis", J Virol, 67, pp.3756~3762 (1993)
45. Carman WF, "Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection", Lancet, 2, pp.588~591 (1989)
46. Buckwold VE, "Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication", J Virol, 70, pp.5845~5851 (1996)
47. Scaglioni PP, "Posttranscriptional regulation of hepatitis B virus replication by the precore protein", J Virol, 71, pp.345~353 (1997)
48. Locarnini S, "Cellular response to conditional expression of the hepatitis B virus precore and core proteins in cultured hepatoma (Huh-7) cells", J Clin Virol, 32, pp.113~121 (2005)
49. Locarnini S, "Cellular and virological mechanisms of HBV drug resistance", J Hepatol, 44, pp.422~431 (2006)
50. Warner N, "The antiviral drug selected hepatitis B virus rtA181T", sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound, 2008, pp.48, 88~98
51. Yuen l, "Evolution of the hepatitis B surface antigen in European and Asian HBV genotypes during the era of antiviral therapy", Hepatol Int, 5, pp.3~558 (2011)
52. Lever A, "Treatment of chronic hepatitis B virus infection with monoclonal antibody to the hepatitis B virus surface antigen in two patients with hypogammaglobulinaemia, In Viral Hep & Liver Dis", pp.961~962 (1987), Alan R Liss Inc
53. Lever AM, "Monoclonal antibody to HBsAg for chronic hepatitis B virus infection with hypogammaglobulinaemia", Lancet, 335, pp.1529~ (1990)
54. Fried MW, "HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B", Hepatology, 47, pp.428~434 (2008)
55. "RFA-DK-07-011. Hepatitis B clinical research network" (2007)[URL]
56. Nuttall SD, "Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70", Eur J Biochem, 270, pp.3543~3554 (2003)
57. Roux KH, "Structural analysis of the nurse shark (new) antigen receptor (NAR): molecular convergence of NAR and unusual mammalian immunoglobulins", Proc Natl Acad Sci U S A, 95, pp.11804~11809 (1998)
58. Ewert S, "Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains", Biochemistry, 41, pp.3628~3636 (2002)
59. Nuttall SD, "Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1", Proteins, 55, pp.187~197 (2004)
60. Stanfield RL, "Crystal structure of a shark single-domain antibody V region in complex with lysozyme", Science, 305, pp.1770~1773 (2004)
61. Streltsov VA, "Structural evidence for evolution of shark Ig new antigen receptor variable domain antibodies from a cell-surface receptor", Proc Natl Acad Sci U S A, 101, pp.12444~12449 (2004)
62. Streltsov VA, "Structure of a shark IgNAR antibody variable domain and modeling of an early-developmental isotype", Protein Sci, 14, pp.2901~2909 (2005)
63. Dandri M, "Animal models for the study of HBV replication and its variants", J Clin Virol, 34(Suppl 1), pp.54~62 (2005)
64. Ladner SK, "Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication", Antimicrob Agents Chemother, 41, pp.1715~1720 (1997)
65. Sells MA, "Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA", Proc Natl Acad Sci U S A, 84, pp.1005~1009 (1987)
66. Rehermann B, "Immunology of hepatitis B virus and hepatitis C virus infection", Nat Rev Immunol, 5, pp.215~229 (2005)
67. Eren R, "Human monoclonal antibodies specific to hepatitis B virus generated in a human", mouse radiation chimera: the Trimera system, 1998, pp.93, 154~161
68. Eren R, "Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees", Hepatology, 32, pp.588~596 (2000)
69. Ilan E, "The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents", Hepatology, 29, pp.553~562 (1999)
70. Dandri M, "Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus", Hepatology, 33, pp.981~988 (2001)
71. Walter E, "Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo", Hepatology, 24, pp.1~5 (1996)
72. Menne S, "The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection", World J Gastroenterol, 13, pp.104~124 (2007)
73. Hamatake RK, "Methods in Molecular Medicine. vol 96: Hepatitis B and D Protocols, vol 2" (2004), Humana Press

관련 논문AI추천